TITLE

The real risk-benefit profile

AUTHOR(S)
Clinton, Patrick
PUB. DATE
January 2007
SOURCE
Pharmaceutical Representative;Jan2007, Vol. 37 Issue 1, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the contents of legal scholar Richard A. Epstein's book "Overdosed: How Excessive Government Regulation Stifles Pharmaceutical Innovation." The policy of the United States Food and Drug Administration is to take almost any step to avoid harming people with drugs even if it means harming people by depriving them of drugs.
ACCESSION #
23620459

 

Related Articles

  • OVERDOSE: HOW EXCESSIVE GOVERNMENT REGULATION STIFLES PHARMACEUTICAL INNOVATION. Rawson, Nigel S. B. // JAMA: Journal of the American Medical Association;2/14/2007, Vol. 297 Issue 6, p646 

    This article reviews the book "Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation," by Richard A. Epstein.

  • FDA VS THE INDIVIDUAL. Epstein, Richard A. // Pharmaceutical Executive;Dec2006, Vol. 26 Issue 12, p78 

    An excerpt from the book "Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation," by Richard A. Epstein is presented.

  • Overdose: How excessive government regulation stifles pharmaceutical innovation. Ross, David B. // Journal of Clinical Investigation;Dec2007, Vol. 117 Issue 12, p3598 

    The article reviews the book "Overdose: How excessive government regulation stifles pharmaceutical innovation," by Richard A. Epstein.

  • Regulation Overdose. Henderson, David R. // Regulation;Summer2010, Vol. 33 Issue 2, p46 

    The article reviews two books on pharmaceutical regulations including "Leviathan's Drug Problem: Federal Monopoly of Pharmaceutical Regulation and Its Deadly Cost," by John R. Graham and "Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation," by Richard A. Epstein.

  • Should we loosen the grip on drug companies? Smith, Richard // BMJ: British Medical Journal (International Edition);9/1/2007, Vol. 335 Issue 7617, p454 

    This article reviews the book "Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation," by Richard A. Epstein.

  • Washington letter.  // DCI;May95, Vol. 156 Issue 5, p8 

    Reports on the reactions of the drug industry analysts on the possible privatization of the Food and Drug Administration (FDA).

  • NEW DOSING STRENGTH.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p78 

    Reports that Ivax Laboratories has updated its packaging for Nasarel Nasal Spray to reflect the Food and Drug Administration-labeling change in the U.S.

  • FDA states policy on pharmacy compounding. Young, Donna // American Journal of Health-System Pharmacy;7/1/2002, Vol. 59 Issue 13, p1222 

    Reports on U.S. Food and Drug Administration's decision to issue a compliance policy guide for pharmacy compounding. Publishing of the guideline in the agency's web site; Criticisms of the pharmacies against the guidelines.

  • News Briefs.  // American Journal of Health-System Pharmacy;3/15/2003, Vol. 60 Issue 6, p546 

    Presents news briefs related to various developments in the pharmaceutical industry as of March 2003. Approval given by the U.S. Food & Drug Administration on the marketing of a traumatic wound dressing made from chitosan derived from Shrimp; Reduction in the risks of hospitalization and death...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics